Published in Nature on November 09, 1987
Poxvirus pathogenesis. Microbiol Rev (1991) 3.54
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A (1996) 3.29
IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol (1995) 2.02
Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways. J Virol (1994) 1.94
Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors. J Exp Med (1997) 1.59
Vaccinia virus vaccines: past, present and future. Antiviral Res (2009) 1.58
Interferon gamma is involved in the recovery of athymic nude mice from recombinant vaccinia virus/interleukin 2 infection. J Exp Med (1990) 1.56
Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J Virol (1996) 1.52
Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol (1996) 1.44
The interferon-inducible chemokines MuMig and Crg-2 exhibit antiviral activity In vivo. J Virol (1999) 1.43
A mechanism for the inhibition of fever by a virus. Proc Natl Acad Sci U S A (1996) 1.39
Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo. Proc Natl Acad Sci U S A (1991) 1.22
Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity. J Virol (2001) 1.21
Construction, replication, and immunogenic properties of a simian immunodeficiency virus expressing interleukin-2. J Virol (1997) 1.20
Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses. Proc Natl Acad Sci U S A (1989) 1.14
Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and gamma interferon are attenuated for nude mice. Proc Natl Acad Sci U S A (1992) 1.12
Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques. J Virol (1997) 1.08
Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice. Proc Natl Acad Sci U S A (2001) 1.06
Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes. J Virol (2004) 1.06
A vaccinia virus double recombinant expressing the F and H genes of rinderpest virus protects cattle against rinderpest and causes no pock lesions. Proc Natl Acad Sci U S A (1991) 1.06
The adenovirus E3 14.7-kilodalton protein which inhibits cytolysis by tumor necrosis factor increases the virulence of vaccinia virus in a murine pneumonia model. J Virol (1994) 1.05
Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity. Proc Natl Acad Sci U S A (1999) 1.04
Heat shock response to vaccinia virus infection. J Virol (1994) 1.04
A single point mutation of Ala-25 to Asp in the 14,000-Mr envelope protein of vaccinia virus induces a size change that leads to the small plaque size phenotype of the virus. J Virol (1989) 1.02
Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment. J Virol (2005) 1.02
Effects of virally expressed interleukin-10 on vaccinia virus infection in mice. J Virol (1993) 1.00
Identification and characterization of a novel GGA/C-binding protein, GBP-i, that is rapidly inducible by cytokines. Mol Cell Biol (1994) 1.00
Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. J Virol (2006) 0.97
Conditional reduction of human immunodeficiency virus type 1 replication by a gain-of-herpes simplex virus 1 thymidine kinase function. Proc Natl Acad Sci U S A (1996) 0.94
Vaccinia virus vectors: new strategies for producing recombinant vaccines. Clin Microbiol Rev (1990) 0.92
Construction and characterization of replication-competent simian immunodeficiency virus vectors that express gamma interferon. J Virol (1996) 0.91
Vaccinia viruses with a serpin gene deletion and expressing IFN-gamma induce potent immune responses without detectable replication in vivo. Proc Natl Acad Sci U S A (2005) 0.89
Comparison of antibody avidity and titre elicited by peptide as a protein conjugate or as expressed in vaccinia. Immunology (1988) 0.89
Reflections on the early development of poxvirus vectors. Vaccine (2013) 0.88
Effect of coexpression of interleukin-2 by recombinant respiratory syncytial virus on virus replication, immunogenicity, and production of other cytokines. J Virol (2000) 0.87
Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice. J Virol (2011) 0.81
Safety mechanism assisted by the repressor of tetracycline (SMART) vaccinia virus vectors for vaccines and therapeutics. Proc Natl Acad Sci U S A (2013) 0.79
Nef from pathogenic simian immunodeficiency virus is a negative factor for vaccinia virus. Proc Natl Acad Sci U S A (2005) 0.79
Influence of vector-encoded cytokines on anti-Salmonella immunity: divergent effects of interleukin-2 and tumor necrosis factor alpha. Infect Immun (2001) 0.78
Use of a recombinant vaccinia virus expressing interferon gamma for post-exposure protection against vaccinia and ectromelia viruses. PLoS One (2013) 0.77
Release of genetically altered viruses into the environment. Br Med J (Clin Res Ed) (1988) 0.75
HIV risk behavior reduction following intervention with key opinion leaders of population: an experimental analysis. Am J Public Health (1991) 7.21
Rapid quantitative detection of chytridiomycosis (Batrachochytrium dendrobatidis) in amphibian samples using real-time Taqman PCR assay. Dis Aquat Organ (2004) 5.77
Diagnostic assays and sampling protocols for the detection of Batrachochytrium dendrobatidis. Dis Aquat Organ (2007) 3.78
Recall of early menstrual history and menarcheal body size: after 30 years, how well do women remember? Am J Epidemiol (2002) 3.11
Heterogeneity and specificity of cloned lines of influenza-virus specific cytotoxic T lymphocytes. J Exp Med (1981) 2.71
Host defenses in experimental scrub typhus: role of cellular immunity in heterologous protection. Infect Immun (1976) 2.60
Long-term body-weight-supported treadmill training and subsequent follow-up in persons with chronic SCI: effects on functional walking ability and measures of subjective well-being. Spinal Cord (2005) 2.18
Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer (1998) 2.06
Postexercise net protein synthesis in human muscle from orally administered amino acids. Am J Physiol (1999) 2.00
Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur J Immunol (1986) 1.90
Activation of leukemia viruses by graft-versus-host and mixed lymphocyte reactions in vitro. Proc Natl Acad Sci U S A (1972) 1.85
A dominant selectable marker for the construction of recombinant poxviruses. Gene (1988) 1.72
Schistosomiasis in the congenitally athymic (nude) mouse. I. Thymic dependency of eosinophilia, granuloma formation, and host morbidity. J Immunol (1977) 1.68
Elevated natural killer cell responses in mice infected with recombinant vaccinia virus encoding murine IL-2. J Immunol (1990) 1.67
Isolated testicular vasculitis mimicking a testicular neoplasm. J Clin Pathol (1994) 1.59
Capripoxviruses: an emerging worldwide threat to sheep, goats and cattle. Transbound Emerg Dis (2008) 1.57
Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res (1995) 1.57
Monoclonal antibodies that protect in vivo against Plasmodium chabaudi recognize a 250,000-dalton parasite polypeptide. Infect Immun (1982) 1.56
Comparative studies of piscine and amphibian iridoviruses. Arch Virol (2000) 1.50
Primary anti-viral cytotoxic T-cell responses in semiallogeneic chimeras are not absolutely restricted to host H-2 type. J Exp Med (1979) 1.46
The clinical efficacy of oral tocolytic therapy. Am J Obstet Gynecol (1996) 1.45
The roles of influenza virus haemagglutinin and nucleoprotein in protection: analysis using vaccinia virus recombinants. Scand J Immunol (1987) 1.41
Testosterone injection stimulates net protein synthesis but not tissue amino acid transport. Am J Physiol (1998) 1.40
Immunologic aspects of host responses to schistosomiasis: resistance, immunopathology, and eosinophil involvement. Prog Allergy (1978) 1.39
Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. J Virol (2004) 1.39
Simultaneous expression of H-2-restricted and alloreactive recognition by a cloned line of influenza virus-specific cytotoxic T lymphocytes. J Exp Med (1981) 1.34
Delayed hypersensitivity granuloma formation and modulation around Schistosoma mansoni eggs in vitro. II. Regulatory T cell subsets. J Immunol (1982) 1.31
Induction of mouse type-C RNA virus by lipopolysaccharide. J Immunol (1975) 1.28
Tropical diseases of importance to the traveler. Adv Intern Med (1984) 1.28
Body weight supported treadmill training in acute spinal cord injury: impact on muscle and bone. Spinal Cord (2005) 1.26
Active suppression as a possible mechanism of tolerance in tetraparental mice. J Exp Med (1973) 1.25
Identification of a schizont- and species-specific surface glycoprotein on erythrocytes infected with rodent malarias. Mol Biochem Parasitol (1982) 1.25
Effects of leucine and its metabolite β-hydroxy-β-methylbutyrate on human skeletal muscle protein metabolism. J Physiol (2013) 1.25
Important curriculum content for baccalaureate allied health programs: a survey of deans. J Allied Health (1992) 1.24
Stage specific protein and nucleic acid synthesis during the asexual cycle of the rodent malaria Plasmodium chabaudi. Mol Biochem Parasitol (1982) 1.23
Cell-mediated immunity in interstitial nephritis. III. T lymphocyte-mediated fibroblast proliferation and collagen synthesis: an immune mechanism for renal fibrogenesis. J Immunol (1980) 1.22
Cellular adaptation to repeated eccentric exercise-induced muscle damage. J Appl Physiol (1985) (2001) 1.22
Fowlpox virus thymidine kinase: nucleotide sequence and relationships to other thymidine kinases. Virology (1987) 1.21
Studies on the control of ribosomal RNA synthesis in HeLa cells. Eur J Biochem (1975) 1.20
Multiple-cloning-site plasmids for the rapid construction of recombinant poxviruses. Gene (1985) 1.18
A general method for the construction of recombinant vaccinia viruses expressing multiple foreign genes. Gene (1988) 1.18
Body mass index and blood pressure in Korean men and women: the Korean National Blood Pressure Survey. J Hypertens (1994) 1.17
Field and vaccine strains of fowlpox virus carry integrated sequences from the avian retrovirus, reticuloendotheliosis virus. Virology (1997) 1.15
Lymphokine modulation of fibroblast proliferation. J Immunol (1982) 1.14
A capripoxvirus detection PCR and antibody ELISA based on the major antigen P32, the homolog of the vaccinia virus H3L gene. J Immunol Methods (1999) 1.13
Cellular immunity in the mouse. II. Correlation of in vivo and in vitro phenomena. Cell Immunol (1972) 1.12
Cell-mediated immunity in interstitial nephritis. I. T lymphocyte systems in nephritic guinea pigs: the natural history and diversity of the immune response. J Immunol (1979) 1.12
Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J Virol (1994) 1.12
Delayed hypersensitivity granuloma formation around Schistosoma mansoni eggs in vitro. I. Definition of the model. J Immunol (1982) 1.11
Cellular immunity in the mouse. I. In vitro lymphocyte reactivity. Cell Immunol (1972) 1.10
Leptin, body composition and bone mineral density in premenopausal women. Calcif Tissue Int (2003) 1.10
Characterization of Schistosoma mansoni antigen-reactive T cell clones that form granulomas in vitro. J Immunol (1985) 1.08
Endothelial function of young healthy males following whole body resistance training. J Appl Physiol (1985) (2005) 1.08
Cell-mediated immune responses to influenza virus antigens expressed by vaccinia virus recombinants. Microb Pathog (1986) 1.07
Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J Immunol (1996) 1.07
Regulation of interleukin 2 receptor expression on murine cytotoxic T lymphocyte clones. J Immunol (1984) 1.06
Vaccinia virus recombinants expressing the SA11 rotavirus VP7 glycoprotein gene induce serotype-specific neutralizing antibodies. J Virol (1987) 1.05
Quantification of hepatic transcribing RNA polymerase molecules, polyribonucleotide elongation rates and messenger RNA complexity in fed and fasted rats. Eur J Biochem (1978) 1.04
Trypanosoma rhodesiense infection in congenitally athymic (nude) mice. Infect Immun (1978) 1.04
Endurance exercise training attenuates leucine oxidation and BCOAD activation during exercise in humans. Am J Physiol Endocrinol Metab (2000) 1.03
Carbohydrate loading and metabolism during exercise in men and women. J Appl Physiol (1985) (1995) 1.03
Serum-mediated immunological non-reactivity between histoincompatible cells in tetraparental mice. Nature (1971) 1.03
Antigen-dependent proliferation of cloned continuous lines of H-2-restricted influenza virus-specific cytotoxic T lymphocytes. J Immunol (1981) 1.03
Murine interstitial nephritis. II. The adoptive transfer of disease with immune T lymphocytes produces a phenotypically complex interstitial lesion. J Immunol (1984) 1.02
Glucose-6 phosphate dehydrogenase deficiency, infectious hepatitis, acute hemolysis, and renal failure. Ann Intern Med (1969) 1.02
Effect of whole body resistance training on arterial compliance in young men. Exp Physiol (2005) 1.02
Adolescents' knowledge of medical terminology and family health history. Health Psychol (1992) 1.01
Unique genome arrangement of an ovine adenovirus: identification of new proteins and proteinase cleavage sites. Virology (1996) 1.01
Infectious bursal disease virus structural protein VP2 expressed by a fowlpox virus recombinant confers protection against disease in chickens. Arch Virol (1993) 1.01
Stripping membranes at term: can it safely reduce the incidence of post-term pregnancies? Obstet Gynecol (1990) 1.01
Polymorphism of genes involved in anti-tubular basement membrane disease in rats. Immunogenetics (1983) 1.01
Activated eosinophils are the major source of Th2-associated cytokines in the schistosome granuloma. J Immunol (1999) 1.01
Solitary fibrous tumour: report of two new locations in the upper respiratory tract. J Laryngol Otol (1993) 1.00
Biological effects of recombinant vaccinia virus-expressed interleukin 4. Cytokine (1992) 1.00
Household tobacco smoke exposure is negatively associated with premenopausal bone mass. Osteoporos Int (2002) 1.00
Resistance exercise enhances mTOR and MAPK signalling in human muscle over that seen at rest after bolus protein ingestion. Acta Physiol (Oxf) (2010) 0.99
Construction of ovine adenovirus recombinants by gene insertion or deletion of related terminal region sequences. Virology (1997) 0.99
Efficacy of influenza haemagglutinin and nucleoprotein as protective antigens against influenza virus infection in mice. Scand J Immunol (1988) 0.99
Activation of virus specific CTL clones: antigen-dependent regulation of interleukin 2 receptor expression. J Immunol (1985) 0.99
Recombinant vaccinia viruses and the development of immunization strategies using influenza virus. J Infect Dis (1989) 0.97
Immune responses to H-2Kd antigen expressed by recombinant vaccinia virus. Proc Natl Acad Sci U S A (1986) 0.97